2.05Open2.05Pre Close0 Volume14 Open Interest70.00Strike Price0.00Turnover2254.79%IV226.39%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry2.05Extrinsic Value100Contract SizeAmericanOptions Type0.2429Delta0.0145Gamma10.77Leverage Ratio-4.9088Theta0.0001Rho2.62Eff Leverage0.0030Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet